Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
China
· Delayed Price · Currency is CNY 8.82
+0.07 (0.80%)
Jun 6, 2025, 2:45 PM CST
SHE:002728 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 42.91 | 20.5 | 253.18 | 178.2 | 126.92 | 43.82 | Upgrade
|
| Depreciation & Amortization | 64.36 | 64.36 | 60.1 | 52.52 | 51.31 | 51.03 | Upgrade
|
| Other Amortization | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0 | -0 | -0.12 | -0.04 | -0.1 | 0.29 | Upgrade
|
| Asset Writedown & Restructuring Costs | 11.79 | 11.79 | 13.44 | 0.12 | 23.43 | 22.45 | Upgrade
|
| Loss (Gain) From Sale of Investments | -3.74 | -3.74 | -0.36 | -0.34 | -6.31 | -15.21 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.04 | -0.04 | 0.07 | 0.6 | 0.1 | -0.92 | Upgrade
|
| Other Operating Activities | 112.3 | 5.95 | 16.32 | 30 | 31.27 | 46.67 | Upgrade
|
| Change in Accounts Receivable | -42.92 | -42.92 | -8.02 | -34.02 | 13.98 | 10.05 | Upgrade
|
| Change in Inventory | 6.7 | 6.7 | -63.6 | -12.75 | 5.39 | -1.51 | Upgrade
|
| Change in Accounts Payable | -85.03 | -85.03 | -72.84 | 157.24 | 13.17 | 16.51 | Upgrade
|
| Change in Other Net Operating Assets | 0.72 | 0.72 | -0.81 | -1.76 | -1.1 | -0.93 | Upgrade
|
| Operating Cash Flow | 106.21 | -22.55 | 198.56 | 371.66 | 256.81 | 168.99 | Upgrade
|
| Operating Cash Flow Growth | -19.70% | - | -46.58% | 44.72% | 51.97% | -23.76% | Upgrade
|
| Capital Expenditures | -109.06 | -113.56 | -86.05 | -90.26 | -109.58 | -89.42 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.22 | 0.02 | 0.16 | 0.09 | 0.52 | 0.03 | Upgrade
|
| Investment in Securities | - | - | - | -13.5 | 250 | 200 | Upgrade
|
| Other Investing Activities | -23.09 | 3.74 | 0.36 | 0.34 | 6.31 | 15.21 | Upgrade
|
| Investing Cash Flow | -131.93 | -109.8 | -85.53 | -103.33 | 147.25 | 125.82 | Upgrade
|
| Short-Term Debt Issued | - | 1,014 | 626.63 | 763.45 | 432.86 | 793.35 | Upgrade
|
| Total Debt Issued | 993.78 | 1,014 | 626.63 | 763.45 | 432.86 | 793.35 | Upgrade
|
| Short-Term Debt Repaid | - | -809 | -965.88 | -517 | -836.12 | -722.68 | Upgrade
|
| Total Debt Repaid | -1,036 | -809 | -965.88 | -517 | -836.12 | -722.68 | Upgrade
|
| Net Debt Issued (Repaid) | -42.22 | 204.78 | -339.26 | 246.45 | -403.26 | 70.67 | Upgrade
|
| Issuance of Common Stock | 11.54 | 13.88 | 282.83 | - | 184.91 | - | Upgrade
|
| Repurchase of Common Stock | -93.86 | -93.86 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -182.1 | -182.31 | -149.02 | -147.62 | -138.38 | -163.97 | Upgrade
|
| Other Financing Activities | 129.91 | -54 | 100 | -200 | - | - | Upgrade
|
| Financing Cash Flow | -176.73 | -111.51 | -105.44 | -101.17 | -356.73 | -93.3 | Upgrade
|
| Net Cash Flow | -202.45 | -243.85 | 7.59 | 167.16 | 47.33 | 201.51 | Upgrade
|
| Free Cash Flow | -2.85 | -136.11 | 112.51 | 281.39 | 147.24 | 79.57 | Upgrade
|
| Free Cash Flow Growth | - | - | -60.02% | 91.11% | 85.05% | -12.42% | Upgrade
|
| Free Cash Flow Margin | -0.35% | -19.79% | 10.54% | 31.74% | 19.42% | 12.58% | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.27 | 0.24 | 0.64 | 0.37 | 0.20 | Upgrade
|
| Cash Income Tax Paid | 61.25 | 62.57 | 101.92 | 67.5 | 67.94 | 64.06 | Upgrade
|
| Levered Free Cash Flow | -30.56 | -148.47 | -14.32 | 175.85 | 60.27 | 13.13 | Upgrade
|
| Unlevered Free Cash Flow | -26.94 | -145.15 | -4.09 | 194.06 | 78.72 | 39.83 | Upgrade
|
| Change in Net Working Capital | 20.95 | 115.47 | 171 | -93 | -25.86 | -13.06 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.